Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD), activity, and safety of oprozomib in patients with hematologic malignancies.

Timeline

Start

2011-10-15

Primary completion

2016-08-08

Completion

2019-08-12

Outcome

Outcome not reported

Stopped (Enrollment): “A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in 2011-001 was halted.”

Drugs

Indications